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The essential role of cardiac troponin in the diagnosis of acute myocardial infarction has led to the development of high-sensitivity
assays, which are able to detect very small amounts of myocardial necrosis. The high-sensitivity cardiac troponin T assay, however,
is not entirely specific for myocardial injury. This case report describes a 48-year-old woman, who, two years after cardiac
transplantation, presented with rhabdomyolysis. During the course of the disease, her troponin T level was elevated on repeated
occasions, but other definitive evidence of myocardial injury was not found. Asymptomatic cardiac troponin T elevations during
rhabdomyolysis may be due to either cardiac involvement or false positive results stemming from skeletal muscle injury.
1. Introduction
Myocardial injury is defined as the disruption of normal
cardiac myocyte membrane integrity leading to release of
intracellular components. These include structural proteins
such as troponin (Tn) and creatine kinase (CK).The essential
role of these myocardial tissue-specific cardiac biomarkers in
the diagnosis of acute myocardial infarction (MI) has led to
the development of high-sensitivity cardiac TnT (hs-cTnT)
and I (hs-cTnI) analyses. The improved sensitivity, however,
comes at the cost of a reduced specificity for MI, as these
new assays have the ability to detect myocardial necrosis
associated with a large number of other conditions. Further-
more, the hs-cTnT assay is not entirely specific formyocardial
injury, and as with any other test, false positive and negative
results do occur [1–3]. Therefore, correct interpretation of
elevated cardiac biomarkers can be challenging. We present
a case in which the elevated cTnT levels probably were not
due to myocardial damage.
2. Case Presentation
A 48-year-old woman, who had undergone cardiac trans-
plantation two years earlier, was admitted to the department
of cardiology due to diarrhea, fatigue, and malaise. The
patient was treated with the usual immunosuppressive reg-
imen, comprising tacrolimus 2mg b.i.d., mycophenolate
mofetil 500mg b.i.d., and prednisone 5mg q.d. She further
received atorvastatin due to concomitant dyslipidemia. A few
months prior to admission, the dose of atorvastatin had been
increased from 40mg to 80mg daily.
Blood tests at admission showed elevated levels of
creatinine at 612 𝜇mol/L (reference range 45–90 𝜇mol/L),
CK 18,934U/L (50–150U/L), and myoglobin 11,718 𝜇g/L
(<75 𝜇g/L). The symptoms and findings were consistent with
a diagnosis of rhabdomyolysis with acute kidney injury,
and a regimen of forced alkaline diuresis was initiated. The
condition was ascribed to the dose increase of atorvas-
tatin and the possible interaction between this drug and
tacrolimus, resulting in a reduced elimination of atorvastatin
[4]. Consequently, atorvastatin was discontinued, and the
dose of tacrolimus was reduced.
On the seventh day of admission, elevated levels of hs-
cTnT at 471 ng/L (99th percentile 14 ng/L) and CK isoenzyme
MB (CK-MB) 162 𝜇g/L (<3 𝜇g/L) alongside increasing levels
of CK 30,750U/L and myoglobin 29,120𝜇g/L were found.
Subsequent serial measurements showed increasing levels
Hindawi Publishing Corporation
Case Reports in Medicine
Volume 2015, Article ID 270204, 3 pages
http://dx.doi.org/10.1155/2015/270204
2 Case Reports in Medicine
of cTnT, but decreasing levels of CK-MB, CK, myoglobin,
and creatinine. Furthermore, the CK-MB/CK ratio increased
from less than 1% initially to 12%. Due to the elevated cardiac
biomarkers, serial electrocardiograms, echocardiograms, and
an endomyocardial biopsy were performed, which were all
unremarkable. A peripheral muscle biopsy showed toxic
myopathy, but no signs of inflammatorymyositis.The patient
was discharged after a total of fourweeks.The statin treatment
was not resumed, and she has not shown any signs of relapse
since.
3. Discussion
Pathologically, an MI is defined as myocardial cell death due
to prolonged ischemia. Therefore, the diagnosis of an acute
MI requires evidence of myocardial necrosis in a clinical
setting consistent with myocardial ischemia. Myocardial
necrosis is defined as a rise and/or fall of cardiac biomarker
values (preferably cTn) with at least one value above the
99th percentile upper reference limit, whereas myocardial
ischemia is defined as at least one of the following: (1)
symptoms of ischemia, (2) new or presumed new significant
ST-segment or T-wave changes or new left bundle branch
block, (3) development of pathological Q waves in the ECG,
(4) imaging evidence of new loss of viable myocardium or
new regional wall motion abnormality, or (5) identification
of an intracoronary thrombus by angiography or autopsy [5].
The Tn complex is part of the contractile system of
skeletal and cardiac muscle and consists of three subunits:
TnC, TnI, and TnT. Cardiac TnC cannot be used as a cardiac
biomarker due to its expression in adult skeletal muscle,
whereas cTnI and cTnT are almost exclusively expressed
in cardiomyocytes. However, cTnT is regularly found in
embryonic skeletal muscle, and its messenger RNA (mRNA)
is sometimes reexpressed in patients with skeletal muscle
disease. These TnT isoforms are similar to those of normal
and diseased myocardium and seem to be detected by the
antibodies used in cTnT assays due to cross-reaction [6, 7].
Although cTnI mRNA is also expressed in skeletal muscle
myopathies, these isoforms apparently go undetected by
the contemporary cTnI assays, enabling one to distinguish
between the presence and absence of myocardial injury [7–
9].
It has been suggested that cTnT elevations detected during
rhabdomyolysis may be the result of reexpression of a specific
isoform seen in regenerating skeletalmuscle, as this condition
is characterized by simultaneous degradation and regenera-
tion of skeletal muscle [10]. The elevated cTnT levels in this
case could therefore be due to regeneration of skeletal muscle
tissue and not myocardial damage, which was also reflected
in the increasing cTnT-levels despite decreasing levels of
CK and myoglobin and particularly the increasing CK-
MB/CK ratio [11]. Furthermore, cardiac involvement during
rhabdomyolysis has been described previously, whereby cTn
elevations should not necessarily be ignored, but at the same
time, the risk of false positive cTnT results increases with
severe skeletal muscle injury [12]. Unfortunately, cardiac
magnetic resonance imaging (MRI) was not done, although
this modality might have provided a more definite answer,
for example, if the patient had more diffuse injury due to
myocarditis or rhabdomyolysis [13].
In the few similar cases described in the literature, the
definitive evidence of cardiac involvement during drug-
induced rhabdomyolysis was provided by autopsy [12, 14,
15]. Furthermore, Punukollu et al. reviewed 91 patients with
rhabdomyolysis ofwhom 19 had elevated cTnI; however, none
of these patients had segmental wall motion abnormalities on
echocardiography [16].
This case report highlights the importance of interpreting
the results of the hs-TnT assay correctly and taking into
account the diagnostic criteria when designating a diagnosis
ofMI: relevant symptoms, ECG-changes, or imaging findings
as well as the compulsory rise and fall pattern in cTn. In
addition, in patients with rhabdomyolysis, serial CK-MB/CK
ratio, cTnI, and cardiac MRI may be helpful in order to
differentiate between cardiac involvement and false positive
cTnT results.
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